Apeloa Pharmaceutical Co.,Ltd
000739
Clasificación en acciones
#4290
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
Precio por acción
$3.13
Capitalización bursátil
$3.62B
Cambio (1 día)
-1.42%
Cambio (1 año)
46.59%
País
CN
Comercio Apeloa Pharmaceutical Co.,Ltd (000739)
Categoría
Healthcare
Ganancias de Apeloa Pharmaceutical Co.,Ltd (000739)
Ganancias en Jun 2026 TTM: $149.15M
Secondo gli ultimi rapporti finanziari di Apeloa Pharmaceutical Co.,Ltd, gli utili attuali della società sono $149.15M. Nel 2024, la società ha registrato un utile di $164.85M, una disminución en comparación con agli utili del 2023, che erano di $170.18M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Apeloa Pharmaceutical Co.,Ltd desde 2000 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $149.15M | -2.13% |
| 2025 | $152.39M | -7.56% |
| 2024 | $164.85M | -3.13% |
| 2023 | $170.18M | 15.99% |
| 2022 | $146.72M | -16.29% |
| 2021 | $175.28M | 19.13% |
| 2020 | $147.13M | 61.66% |
| 2019 | $91.01M | 35.45% |
| 2018 | $67.19M | 28.72% |
| 2017 | $52.20M | 8.08% |
| 2016 | $48.30M | 26.97% |
| 2015 | $38.04M | -37.54% |
| 2014 | $60.90M | 79.55% |
| 2013 | $33.92M | 25.69% |
| 2012 | $26.99M | 83.30% |
| 2011 | $14.72M | 255.37% |
| 2010 | $4.14M | -25.11% |
| 2009 | $5.53M | 37.62% |
| 2008 | $4.02M | -6.10% |
| 2007 | $4.28M | -48.53% |
| 2006 | $8.32M | 30.32% |
| 2005 | $6.38M | 8.44% |
| 2004 | $5.89M | -2.73% |
| 2003 | $6.05M | -2.07% |
| 2002 | $6.18M | -300.22% |
| 2001 | $-3.09M | 423.46% |
| 2000 | $-589.59K | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 1,083.07% |
IN
|
